Development of Biodegradable Controlled Release Scleral Systems of Triamcinolone Acetonide

被引:8
作者
Blatsios, G. [1 ,2 ]
Tzimas, A. S. [2 ]
Mattheolabakis, G. [3 ]
Panagi, Z. [3 ]
Avgoustakis, K. [3 ]
Gartaganis, S. P. [2 ]
机构
[1] Med Univ Innsbruck, Univ Clin Ophthalmol & Optometry, Dept Ophthalmol & Optometry, Innsbruck, Austria
[2] Univ Patras, Dept Ophthalmol, Sch Med, Rion, Greece
[3] Univ Patras, Pharmaceut Technol Lab, Dept Pharm, Rion, Greece
关键词
Aqueous; Biodegradable; Controlled release; Eye; Poly(lactide); Scleral; Triamcinolone; Vitreous; DIABETIC MACULAR EDEMA; TRANSSCLERAL DRUG-DELIVERY; INTRAVITREAL TRIAMCINOLONE; INTRASCLERAL IMPLANT; NEOVASCULAR DISEASES; TRABECULAR MESHWORK; SUSTAINED-RELEASE; OCULAR BARRIERS; CROSS-LINKING; MG;
D O I
10.3109/02713683.2010.497599
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To develop scleral controlled-release-systems of triamcinolone acetonide (TA) based on biodegradable poly(lactide) (PLA). Materials and Methods: (1) PLA microspheres containing TA were prepared by a single or double emulsification-solvent evaporation method. Morphology, size, effect of drug input and method of microsphere preparation on drug loading, and in vitro TA release of the microspheres were investigated. (2) Mini-tablets consisting of blank PLA-microspheres and TA (weight ratios of 1:1, 2:1, and 4:1, respectively) were developed and their release profile in vitro was evaluated. (3) The in vitro transscleral diffusion profile was evaluated by placing a PLA-TA (1:1) tablet in a donor chamber and measuring the TA concentration in a receptor chamber. Donor and receptor chambers were separated by rabbit sclera. (4) Two cadaver rabbit eyes received a 1:1 PLA-TA tablet episclerally, which was covered by a scleral patch. TA aqueous humor and vitreous concentrations were measured 5, 10, and 20 days post implantation. Results: (1) Microsphere average size was 2 mu m. The double emulsification method and increasing drug input led to an increase in drug loading and encapsulation. Sustained release of TA over several days from the microspheres in vitro was observed, with the rate of release being affected by their TA content. (2) TA exhibited sustained release profile from the PLA-TA tablets, with the rate of release being affected by the PLA: TA ratio. (3) TA could slowly cross the sclera tissue in vitro, with approximately 21% of the drug loaded in the donor compartment being diffused through the sclera in 45 days. (4) Following scleral administration of the PLA-TA mini-tablets, TA accumulated in the vitreous and aqueous humor of cadaver eyes. Conclusions: The PLA-TA microspheres and mini-tablets appear promising for the controlled transscleral delivery of TA and justify further investigation.
引用
收藏
页码:916 / 924
页数:9
相关论文
共 57 条
[41]   Intracameral Triamcinolone Acetonide as Treatment for Endothelial Allograft Rejection After Penetrating Keratoplasty [J].
Maris, Peter. J. G., Jr. ;
Correnti, Anthony J. ;
Donnenfeld, Eric D. .
CORNEA, 2008, 27 (07) :847-850
[42]   Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes [J].
Mason, JO ;
Somaiya, MD ;
Singh, RJ .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2004, 24 (06) :900-904
[43]   THE INFLUENCE OF SUBSTITUTION TYPE ON THE PERFORMANCE OF METHYLCELLULOSE AND HYDROXYPROPYLMETHYCELLULOSE IN GELS AND MATRICES [J].
MITCHELL, K ;
FORD, JL ;
ARMSTRONG, DJ ;
ELLIOTT, PNC ;
HOGAN, JE ;
ROSTRON, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 100 (1-3) :143-154
[44]   Trans-scleral diffusion of triamcinolone acetonide [J].
Mora, P ;
Eperon, S ;
Felt-Baeyens, O ;
Gurny, R ;
Sagodira, S ;
Breton, P ;
Guex-Crosier, Y .
CURRENT EYE RESEARCH, 2005, 30 (05) :355-361
[45]   Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate [J].
Okabe, J ;
Kimura, H ;
Kunou, N ;
Okabe, K ;
Kato, A ;
Ogura, Y .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (02) :740-744
[46]   Intravitreal triamcinolone acetonide [J].
Peyman, GA ;
Moshfeghi, DM .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2004, 24 (03) :488-490
[47]   Intraocular pressure alterations following intravitreal triamcinolone acetonide [J].
Rhee, D. J. ;
Peck, R. E. ;
Belmont, J. ;
Martidis, A. ;
Liu, M. ;
Chang, J. ;
Fontanarosa, J. ;
Moster, M. R. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (08) :999-1003
[48]   A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide [J].
Robinson, MR ;
Lee, SS ;
Kim, H ;
Kim, S ;
Lutz, RJ ;
Galban, C ;
Bungay, PM ;
Yuan, P ;
Wang, NS ;
Kim, J ;
Csaky, KG .
EXPERIMENTAL EYE RESEARCH, 2006, 82 (03) :479-487
[49]   Chronic alcohol feeding induces biochemical, histological, and functional alterations in rat retina [J].
Sancho-Tello, Maria ;
Muriach, Maria ;
Barcia, Jorge ;
Bosch-Morell, Francisco ;
Genoves, Jose M. ;
Johnsen-Soriano, Siv ;
Romero, Belen ;
Almansa, Inmaculada ;
Diaz-Llopis, Manuel ;
Garcia-Delpech, Salvador ;
Roma, Joaquin ;
Romero, Francisco J. .
ALCOHOL AND ALCOHOLISM, 2008, 43 (03) :254-260
[50]   Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema [J].
Spandau, UHM ;
Derse, M ;
Schmitz-Valckenberg, P ;
Papoulis, C ;
Jonas, JB .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (08) :999-1003